NBRLBoston has been developing the novel anti-tumor immune gene mRNA/DNA combo with iPS derived universal NK and T cells, and steam cell based therapeutic candidates, and TCRm and CAR NK candidates that are the highest level of innovative research and development for anti-cancer immune drugs development.
Our developed anti solid tumor mRNA/DNA gene drug combo with human PBMC derived T and NK cell therapeutic candidates have demonstrated strong efficacy on the inhibition of solid tumor growth in vitro and in vivo studies by improving cytotoxicity T and NK killing tumor cell function, blocking negative signals, and specializing in the tumor micro-environment normalization through the balance of various cytokines/immune cells/blood supply etc. involved in immune activity against tumor.
